Diabetic Retinopathy (DR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Diabetic Retinopathy (DR) Market Outlook

Thelansis’s “Diabetic Retinopathy (DR) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Retinopathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Retinopathy (DR) Overview

Diabetic retinopathy (DR) is a microvascular disorder affecting the retina and arises as a complication of diabetes. It is linked to concurrent microvascular alterations in the brain, heart, kidneys, and peripheral nerves. The symptoms of this condition encompass blurred vision, sudden occurrences of dark "floaters" in the visual field, fluctuating vision, and the emergence of dark or empty patches in one's vision. The likelihood of developing diabetic retinopathy hinges on the duration and type of diabetes mellitus. In instances where type 1 diabetes persists for 15 years or more, the risk escalates to 98%, while for type 2 diabetes with a similar duration, the risk reaches 78%. The precise mechanisms through which elevated blood sugar levels lead to diabetic retinopathy's development and the visible histopathological alterations still require complete clarification. Diabetic retinopathy is categorized into nonproliferative and proliferative forms, contingent on the presence or absence of ocular neovascularization. Nonproliferative diabetic retinopathy (NPDR) is typified by anomalies in the retinal vasculature, including microaneurysms, intraretinal hemorrhages, venous beading, cotton wool spots, hard exudates, capillary nonperfusion, and macular edema. Individuals with diabetic retinopathy experience the emergence of permeable and leaky blood vessels that impact the light-sensitive photoreceptor layer at the rear of the eye. Treating diabetic retinopathy involves laser photocoagulation (PR) or the administration of steroids.

• Globally, diabetic retinopathy's prevalence among diabetes patients is estimated at 27.0%, culminating in 400,000 cases of blindness worldwide.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: